APA (7th ed.) Citation

M, M., A, S., A, A., S, B., M, B., E, V., . . . SE, R. (2026). Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: A sub-analysis of the MEET-URO 33 study. Cancer immunology, immunotherapy : CII, 75(3), 66. https://doi.org/10.1007/s00262-026-04318-x

Chicago Style (17th ed.) Citation

M, Maffezzoli, et al. "Effectiveness of ICI-ICI Versus ICI-TKI Combinations in Patients with IMDC Intermediate- and Poor-risk Metastatic Renal Cell Carcinoma: A Sub-analysis of the MEET-URO 33 Study." Cancer Immunology, Immunotherapy : CII 75, no. 3 (2026): 66. https://doi.org/10.1007/s00262-026-04318-x.

MLA (9th ed.) Citation

M, Maffezzoli, et al. "Effectiveness of ICI-ICI Versus ICI-TKI Combinations in Patients with IMDC Intermediate- and Poor-risk Metastatic Renal Cell Carcinoma: A Sub-analysis of the MEET-URO 33 Study." Cancer Immunology, Immunotherapy : CII, vol. 75, no. 3, 2026, p. 66, https://doi.org/10.1007/s00262-026-04318-x.